Rafferty Asset Management
LXEO icon

Rafferty Asset Management’s Lexeo Therapeutics LXEO Stock Holding History

Rafferty Asset Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$314K Sell
67,535
-33,361
-33% -$180K ﹤0.01% 1001
2026
Q1 		$579K Sell
100,896
-1,263
-1% -$8.95K ﹤0.01% 866
2025
Q4 		$1.01M Buy
+102,159
New +$932K ﹤0.01% 796

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Rafferty Asset Management's LXEO Position: Q2 2026 in Review

Rafferty Asset Management reduced its Lexeo Therapeutics (LXEO) stake by 33% in Q2 2026, selling an estimated $180K and leaving 67,535 shares worth $314K. The position accounts for ﹤0.01% of the portfolio, ranked #1001.

Rafferty Asset Management first reported a position in LXEO in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.01M in Q4 2025. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Rafferty Asset Management held 67,535 shares of Lexeo Therapeutics worth $314K as of Q2 2026.
  • Rafferty Asset Management sold 33,361 Lexeo Therapeutics shares in Q2 2026, an estimated $180K.
  • Lexeo Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #1001 holding.
  • Rafferty Asset Management first reported a position in Lexeo Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Rafferty Asset Management's Lexeo Therapeutics position peaked at $1.01M in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.